Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer

NCT02089334 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Renal Cell Cancer

Interventions

DRUG: RX-0201

Sponsor

Rexahn Pharmaceuticals, Inc.